Month: October 2026

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

Capsoil® Technologies acquires Red Mesa Science & Refining

TowneBank Enhances North Carolina Presence Through Agreement to Acquire blueharbor bank

– Acquired Significantly Below Replacement Cost –
– 2026 Year-to-Date Investments Total $439 Million –

FORM 8.3

FORM 8.3

Kylo Peptides has introduced a bulk research program for high-volume laboratories, with lot reservation & per-lot COAs from four independent laboratories.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

Madrid, 6 October.- Listed technology services company Lleida.net (BME:LLN, EPA:ALLLN) has increased the SMS traffic it delivers to Spanish operators by 40% since January, driven by mandatory sender registration.

Madrid, 6 de octubre.- La cotizada de servicios tecnológicos Lleida.net (BME:LLN, EPA:ALLLN) ha aumentado un 40% desde enero el tráfico de SMS que entrega a los operadores españoles, impulsado por el registro obligatorio de remitentes. 

El crecimiento se aceleró con los primeros pasos de la regulación y se ha disparado desde su aplicación definitiva, el pasado 15 de septiembre. España es el principal destino del tráfico de SMS de la compañía.

Lleida.net calcula que su cuota de mercado se sitúa entre el 20% y el 25% del tráfico de SMS de calidad en España, que es el tráfico transaccional y no publicitario, como los códigos de verificación en dos pasos y las notificaciones. El registro de remitentes ha permitido a la compañía calcular esa cuota.

Desde el 15 de septiembre, los operadores de telecomunicaciones deben bloquear los SMS, MMS y RCS que usan como remitente un nombre comercial o alias no inscrito en el Registro de alias de la CNMC, o que llegan a través de un proveedor no autorizado en ese registro. La medida nace de la Orden TDF/149/2025 y de la Circular 1/2026 de la CNMC, y su objetivo es frenar el smishing, el fraude por SMS que suplanta a bancos, empresas y administraciones.

“Durante años, cualquiera podía hacerse pasar por un banco o por una administración en la pantalla de un móvil. Que cada remitente tenga que estar identificado devuelve la confianza a un canal que usan a diario millones de personas, y premia a las empresas que trabajan de forma legítima”, afirmó Sisco Sapena, CEO y fundador de Lleida.net.

Lleida.net es operador de telecomunicaciones con numeración propia asignada por la CNMC, y puede asignar número a sus clientes. Con el registro, el tráfico de las grandes plataformas de mensajería se dirige hacia los proveedores autorizados.

El registro también ha impulsado la actividad de los clientes de la compañía, que han aumentado su tráfico con Lleida.net después de inscribir sus remitentes.

Fundada en 1995, Lleida.net es uno de los principales proveedores europeos de servicios de notificación certificada, de contratación electrónica y de firma digital. La compañía posee más de 300 patentes en más de 60 países y cotiza en BME Growth (Madrid) y Euronext Growth (París), así como en Frankfurt y Stuttgart.

Kylo Peptides review examines the supplier’s lot-matched COAs, HPLC and LC-MS testing, and independent lab documentation for researchers.

BPCE and Banco Sabadell announce BPCE’s friendly acquisition of a participation in Banco Sabadell and their intention to explore strategic cooperation

 BPCE et Banco Sabadell annoncent l’acquisition par BPCE d’une participation amicale dans Banco Sabadell et leur intention d’explorer des coopérations stratégiques

Schindellegi, Switzerland – 5 October 2026

London, UK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Prop firm Starfunded is developing its offering around clearer program conditions, dedicated trader support and greater flexibility as the prop trading industry continues to evolve.

The closed-door summit will examine how tokenization is reshaping global capital markets.

GUANGZHOU, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — YSX TECH. CO., LTD (NASDAQ: “YSXT”) (the “Company”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced that it will hold an extraordinary general meeting of shareholders (the “EGM”), on October 19, 2026 at 12:00 a.m. Eastern Time, at Room 102, Building 1, No. 22, Huazhou Road, Haizhu District, Guangzhou, Guangdong, China , for the purpose of considering and voting on the following proposals:

TokBoostly Introduces Guide to TikTok Voice Comments and Comment Engagement

Kansas City, Mo., Oct. 05, 2026 (GLOBE NEWSWIRE) — CPESN® USA, a clinically integrated, nationwide organization of pharmacy networks advancing community-based pharmacy practice, today announced that Sanjay Patel, RPh, has been named the recipient of the 2026 CPESN Luminary of the Year Award, sponsored by Prasco.